Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Core Viewpoint - Genprex, Inc. has been selected to present its Acclaim-3 Phase 1/2 clinical trial design for Reqorsa Gene Therapy in combination with Tecentriq at the 2025 ASCO Annual Meeting, highlighting its commitment to advancing cancer treatment options [1][2]. Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes [3]. - The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is under evaluation for treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [3]. - Genprex's oncology program employs a non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles to encapsulate gene-expressing plasmids for intravenous administration [3]. Clinical Trial Details - The Acclaim-3 clinical trial will evaluate the combination of Reqorsa Gene Therapy and Tecentriq as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC) [1][2]. - The trial design will be presented in a poster session on May 31, 2025, by Dr. Bo Wang [2]. Regulatory Designations - Genprex's lung cancer clinical programs have received Fast Track Designation from the FDA, and the SCLC program has also received Orphan Drug Designation [3].